Patrys Dividends and Buybacks

Dividend criteria checks 0/6

Patrys does not have a record of paying a dividend.

Key information

n/a

Dividend yield

-0.05%

Buyback Yield

Total Shareholder Yield	-0.05%
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Nov 08

Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

Mar 24

Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year

Nov 09

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if PAB's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PAB's dividend payments have been increasing.

Dividend Yield vs Market

Patrys Dividend Yield vs Market

How does PAB dividend yield compare to the market?
Segment	Dividend Yield
Company (PAB)	n/a
Market Bottom 25% (AU)	2.6%
Market Top 25% (AU)	6.0%
Industry Average (Biotechs)	2.3%
Analyst forecast (PAB) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate PAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate PAB's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PAB has not reported any payouts.

Patrys Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Patrys Limited, Annual General Meeting, Nov 22, 2024

Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.003 loss in FY 2023)

New major risk - Market cap size

New major risk - Share price stability

New major risk - Market cap size

New major risk - Market cap size

Here's Why It's Unlikely That Patrys Limited's (ASX:PAB) CEO Will See A Pay Rise This Year

Patrys Limited Announces Retirement of Suzy Jones as Director

Full year 2023 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2022)

Patrys Limited, Annual General Meeting, Nov 15, 2023

New minor risk - Financial data availability

Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

First half 2023 earnings released: AU$0.002 loss per share (vs AU$0.002 loss in 1H 2022)

Patrys Limited Appoints Charmaine Gittleson as the Chairman of the Board of Directors, Effective November 16, 2022

No independent directors

Here's Why Some Shareholders May Not Be Too Generous With Patrys Limited's (ASX:PAB) CEO Compensation This Year

Patrys Limited Announces New Preclinical Data for its Full-Sized IgG Antibody, Pat-DX3

Patrys Limited, Melbourne Ordinary Shares to Be Deleted from OTC Equity

Will Patrys (ASX:PAB) Spend Its Cash Wisely?

Patrys Limited Announces Appointment of Mr. Stefan Ross as Non-Executive Director

Full year 2022 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2021)

Patrys Limited Announces Update on PAT-DX1 From Engineering Run Meets all Specification Tests

Patrys Limited Announces New Pre-Clinical Data for Its Lead Asset, Pat-Dx1

Patrys Limited Announces Successful Completion of Pat-Dx1 Engineering Run

Is Patrys (ASX:PAB) In A Good Position To Invest In Growth?

No independent directors

We're Not Very Worried About Patrys' (ASX:PAB) Cash Burn Rate

MD, CEO & Executive Director exercised options to buy AU$360k worth of stock.

Full year 2021 earnings released: AU$0.003 loss per share (vs AU$0.003 loss in FY 2020)

Patrys Limited Provides This Interim Update on Its PAT-DX1 Clinical Trial Program

Patrys Limited Announces Full Size Deoxymab PAT-DX3 Able to Cross the Blood Brain Barrier

Patrys Limited Announces the Publication of New Preclinical Data for Its Deoxymab Antibody PAT-DX1

We're Hopeful That Patrys (ASX:PAB) Will Use Its Cash Wisely

Companies Like Patrys (ASX:PAB) Are In A Position To Invest In Growth

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.002 loss in 1H 2020)

Patrys Limited Successfully Establishes PAT-DX1 Stable Cell Line

What Can We Make Of Patrys' (ASX:PAB) CEO Compensation?

Patrys Limited Adds Full Human Antibody to Deoxymab Portfolio

Earnings released

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies